A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Rizatriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 30 Jan 2012 Results published in the Headache.
    • 05 Nov 2010 Actual end date changed from Jun 2008 to Sep 2010 as reported by ClinicalTrials.gov.
    • 27 Jun 2010 Saftey and pharmacokinetic outcomes were reported at the 52nd Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top